Research & Development
Eccogene's investigational new drug application to start ECC4703 US phase one trial receives FDA approval
2 August 2022 -

Eccogene, a China-based clinical stage biopharmaceutical company, announced on Monday that it has received approval from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application to start phase one trial of its thyroid hormone receptor agonist ECC4703 in the United States.

The study is intended to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants and subjects with elevated LDL.

ECC4703 was discovered from the company's internal drug discovery platform and is a beta-selective, liver targeting THR full agonist. The company said that it has showcased superiority in pre-clinical studies over partial agonist MGL-3196 and has also indicated robust efficacy in pre-clinical models of non-alcoholic steatohepatitis (NASH) and dyslipidemia.



Related Headlines